secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0001558370-25-003013
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics closes $33.1M convertible note, increases authorized shares to 260M
--------------------------------------------------------------------------------

- Issued $33.1M convertible note to Avondale Capital on March 13, 2025; proceeds used to repay $32.91M Streeterville note.
- Stockholders approved increase in authorized common shares from 60M to 260M, effective March 11.
- Annual Meeting elected directors: Julian Gangolli, Ralph Thurman, Lawrence Kenyon to Class III.
- Stockholders approved potential issuance of >19.99% of outstanding common stock upon note conversion.
- Ratified KPMG as auditor for FY2025; advisory say-on-pay passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/0001558370-25-003013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/otlk-20250311x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer